Inogen, Inc. (INGN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Inogen, Inc. (INGN) Healthcare & Pipeline Overview

Inogen, Inc. specializes in portable oxygen concentrators, offering solutions for chronic respiratory conditions. With its Inogen One system, the company targets patients, physicians, and third-party payors in the United States and internationally. The company faces competition in the medical device sector while addressing the growing need for respiratory care.

What Is the Investment Thesis for INGN?

Inogen, Inc. presents a mixed investment case. The company's focus on portable oxygen concentrators addresses a growing need for respiratory care, particularly among aging populations. However, Inogen's negative profit margin of -7.1% raises concerns about profitability. The company's gross margin of 47.6% indicates potential for improvement through cost management and pricing strategies. Key growth catalysts include expanding market reach and product innovation. Potential risks include competition from established medical device companies and regulatory changes. With a beta of 1.71, the stock demonstrates higher volatility compared to the market. Investors should carefully weigh these factors when evaluating Inogen's long-term investment potential.

Based on FMP financials and quantitative analysis

INGN Key Highlights

Market capitalization of $140M reflects the company's current valuation in the market.

• Gross margin of 47.6% indicates the profitability of Inogen's core operations before operating expenses.
• Negative profit margin of -7.1% signals potential challenges in achieving overall profitability.
• Beta of 1.71 suggests higher volatility compared to the broader market, which may appeal to risk-tolerant investors.
• The company serves patients, physicians, clinicians, and third-party payors in the United States and internationally, showcasing a broad customer base.

Who Are INGN's Competitors?

INGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are INGN's Key Strengths?

Innovative portable oxygen concentrator technology.

• Direct-to-patient sales and rental model.
• Established brand recognition in the respiratory care market.

What Are INGN's Weaknesses?

Negative profit margin.

• High beta indicating stock volatility.
• Reliance on a specific product category.

What Could Drive INGN Stock Higher?

Potential regulatory approvals for new products or indications.

• Expansion of direct-to-patient sales and rental programs.
• Strategic partnerships with healthcare providers and distributors.

What Are the Key Risks for INGN?

Financial-distress signal — its Altman Z-Score of 1.32 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-13.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Increased competition from established medical device companies.
• Changes in reimbursement policies for oxygen therapy.
• Negative profit margin impacting financial performance.

What Are the Growth Opportunities for INGN?

• Expansion into International Markets: Inogen has the opportunity to expand its presence in international markets, particularly in regions with aging populations and increasing prevalence of respiratory diseases. By establishing strategic partnerships and distribution networks, Inogen can tap into new customer bases and drive revenue growth. The global respiratory care devices market is projected to reach $27.8 billion by 2027, presenting a significant opportunity for Inogen to increase its market share.
• Product Innovation and Development: Inogen can invest in research and development to create innovative oxygen therapy solutions that address unmet patient needs. This includes developing smaller, lighter, and more efficient portable oxygen concentrators, as well as integrating telehealth capabilities for remote patient monitoring and management. By staying at the forefront of technological advancements, Inogen can maintain a competitive edge and attract new customers.
• Strategic Partnerships and Acquisitions: Inogen can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and customer base. Partnering with home healthcare providers, respiratory clinics, and telehealth companies can provide access to new distribution channels and patient populations. Acquiring complementary businesses can add new technologies and capabilities, strengthening Inogen's position in the market.
• Focus on Direct-to-Consumer Marketing: Inogen can enhance its direct-to-consumer marketing efforts to increase brand awareness and drive sales. This includes utilizing online advertising, social media, and patient education programs to reach potential customers and highlight the benefits of Inogen's portable oxygen concentrators. By building a strong brand reputation and engaging directly with consumers, Inogen can increase customer loyalty and market share.
• Expansion into Adjacent Therapeutic Areas: Inogen can leverage its expertise in respiratory care to expand into adjacent therapeutic areas, such as sleep apnea and asthma. By developing or acquiring products and services that address these conditions, Inogen can diversify its revenue streams and tap into new market segments. The market for sleep apnea devices is projected to reach $12.5 billion by 2028, presenting a significant growth opportunity for Inogen.

What Are INGN's Competitive Advantages?

• Proprietary technology in portable oxygen concentrators.
• Established brand reputation and customer loyalty.
• Distribution network and relationships with healthcare providers.

What Does INGN Do?

Inogen, Inc., established in 2001 and headquartered in Goleta, California, is a medical technology company focused on developing, manufacturing, and marketing portable oxygen concentrators (POCs). The company was founded to improve the lives of individuals suffering from chronic respiratory conditions by providing them with greater mobility and independence. Inogen's flagship product, the Inogen One, is a portable device that concentrates ambient air to deliver supplemental oxygen, eliminating the need for traditional oxygen tanks. This innovation allows patients to maintain an active lifestyle while receiving necessary oxygen therapy. In addition to the Inogen One, the company offers Inogen At Home stationary oxygen concentrators and Inogen Tidal Assist Ventilators, catering to various patient needs and care settings. Inogen serves a diverse customer base, including patients, physicians, clinicians, and third-party payors, both in the United States and internationally. The company also generates revenue through direct rentals of its products to patients. In a competitive landscape, Inogen strives to differentiate itself through technological innovation, product quality, and a commitment to improving patient outcomes.

What Products and Services Does INGN Offer?

• Develops portable oxygen concentrators for patients with chronic respiratory conditions.
• Manufactures oxygen concentrators that concentrate air to provide supplemental oxygen.
• Markets its products to patients, physicians, clinicians, and third-party payors.
• Offers the Inogen One, a portable device for long-term oxygen therapy.
• Provides Inogen At Home stationary oxygen concentrators for home use.
• Offers Inogen Tidal Assist Ventilators and related accessories.
• Rents its products directly to patients.

How Does INGN Make Money?

• Sells portable oxygen concentrators to patients, physicians, and healthcare providers.
• Generates revenue through direct rentals of its products to patients.
• Markets its products through a direct sales force and distribution network.

What Industry Does INGN Operate In?

Inogen operates within the medical device industry, specifically focusing on respiratory care. The market for oxygen therapy is driven by the increasing prevalence of chronic respiratory diseases, such as COPD and asthma, and an aging global population. The industry is competitive, with established players and emerging companies vying for market share. Inogen differentiates itself through its focus on portable oxygen concentrators, offering patients greater mobility and convenience compared to traditional oxygen tanks. The global respiratory care devices market is expected to continue growing, driven by technological advancements and increasing demand for home healthcare solutions.

Who Are INGN's Key Customers?

• Patients with chronic respiratory conditions, such as COPD and asthma.
• Physicians and other clinicians who prescribe oxygen therapy.
• Third-party payors, including insurance companies and government healthcare programs.

Company Profile

Inogen, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Beverly, US. The company is led by CEO Kevin R. Smith. INGN has traded publicly since 2014.

Inogen, Inc. Financial Trajectory

Inogen, Inc. (INGN) reported $95.1M in revenue for Q2 FY2026, reflecting 11.7% growth compared to the prior quarter. The company recorded a net loss of $3.9M, with diluted EPS of $-0.14. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, INGN averaged $-0.23 in diluted EPS.

How Inogen, Inc. Is Valued

Inogen, Inc. carries a market capitalization of $140M, placing it in the micro-cap category. Relative to its peer group, INGN's quantitative score of 36/100 is below the peer average of 57/100.

Return on equity for Inogen, Inc. stands at -13.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.9%, the inverse of the P/E and a quick read on earnings relative to price.

Inogen, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.32 places it in the distress zone, a signal of elevated financial risk.

Inogen, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 22.5% above estimates on average.

Over the past six months, Inogen, Inc. insiders filed 17 SEC Form 4 transactions — 4 sales and 13 purchases. On net that is roughly 401K shares acquired (about $165K) — insiders putting money in tends to read as conviction.

INGN Financials

INGN Latest News

INGN Analyst Consensus

INGN MoonshotScore

Latest Inogen, Inc. Analysis

Common Questions About INGN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources